Effect of metformin, pioglitazone and vitaminE E in patients with non-alcoholic fatty liver disease
Not Applicable
- Conditions
- non-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT2016010411991N3
- Lead Sponsor
- Vice chancellor for research,Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 93
Inclusion Criteria
patients with non-alcoholic fatty liver disease according to sonographic findings; Having age between 17 to 50 years; Having negative serology of viral hepatitis; Willingness to participate in the study. Exclusion criteriain: having obvious presentations of hepatic diseases; history of jaundice; taking steroids; alcohol drinking; diabetes; pregnancy; hypothyroidism; renal failure.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of fatty liver. Timepoint: before and 12 weeks after the interventions. Method of measurement: according to echogenicity of the liver and its comparison with the adjacent kidney, and also comparison with echogenicity of the spleen, and the view of diaphragm and perivascular region of the intrahepatic vessels.;Serum level of liver function tests (AST, ALT, Alkp). Timepoint: before and 12 weeks after the interventions. Method of measurement: (IU/l) by diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).
- Secondary Outcome Measures
Name Time Method Body mass index(BMI). Timepoint: before and 12 weeks after the interventions. Method of measurement: (Kg/m2).;Insulin resistance index(HOMA-IR). Timepoint: before and 12 weeks after the interventions. Method of measurement: [fasting glucose (mg/dl) × insulin (µU/ml)]/ 405.;Fasting blood sugar. Timepoint: before and 12 weeks after the interventions. Method of measurement: mg/dlby diagnostic laboratory kits (Pars Azmoon, Iran) and the auto analyzer (Hitachi 902).;Serum level of insulin. Timepoint: before and 12 weeks after the interventions. Method of measurement: (µu/ml) by Monobind ELISA kit (Monobind, USA).